Markets
US-TECHNOLOGY-LIFESTYLE-ELECTRONICS
A Palantir Technologies Skykit (Patrick T. Fallon/Getty Images)

Retail traders’ zest for Palantir put to the test as earnings await

High multiples usually mean high expectations, but Palantir’s profits are expected to nearly halve year on year.

It’s earnings day for Palantir, arguably the hottest retail stock of the moment.

That steadfast retail shareholder base came in handy after Palantir endured a pretty gnarly 19% drop between January 3 and January 13 amid a wobble in confidence around the highest flyers of the AI era.

Retail traders swooped in to buy the dip and for weeks they’ve been laughing, as the stock recovered its loss and then some. Shares recently hit record highs. Nice trade.

Still, the nagging question posed by Palantir’s insane valuation multiples — forward PE (173x), trailing PE (418x), price-to-forward sales (53x) — remains: is there a snowball’s chance in hell of Palantir’s sales, profits, and margins ever reaching a level that would come anywhere near justifying the company’s nearly $190 billion market valuation?

For what it’s worth, that level of market cap puts Palantir, which has been public for less than five years and in the black for just two, ahead of perennially profitable icons of corporate America like AT&T, Verizon, and Pfizer, to name a few.

Of course, there’s no way that today’s numbers — due around 5 p.m. ET — will answer that question conclusively. Even if Palantir blew the doors off the hinges and posted sales well above the consensus expectation of $771 million and a far fatter profit than the somewhat piddling $48 million that’s projected, the stock would still be laughably overvalued by any traditional metric.

As far as the details, analysts and traders are going to be especially interested in whether Palantir sees a Q4 fillip in sales to corporate clients rather than its larger business of selling defense and intelligence software to governments and militaries. Palantir has been talking up the demand for its AI software products from private-sector buyers recently.

But if the numbers fall far short, it stands to reason it could take some wind out of the stock’s sails.

Shareholders may rightly wonder whether the superheated rhetoric emanating from Palantir executives might actually be an attempt to sex up a fairly standard software business. A bad quarter could also prompt shareholders to take a second look at the fact that the CEO has picked up the pace of his share sales (albeit through a prearranged stock sale program) and has dumped over $2 billion worth of Palantir stock in the last six months, according to one analyst.

Or maybe not. In many ways, we’re in something of a LOL-nothing-matters market.

Case in point: traditional business metrics like sales and profits have proven a remarkably poor guide predictor for Tesla’s share price recently, so much so that flummoxed Wall Street analysts are going public with the fact that they’re at a loss to explain the stock’s rise in the face of obviously ugly earnings last week.

Tesla is an interesting comp for Palantir. Both companies are wealth vehicles of right-wing oligarchs with close ties to the Trump administration. Both have rabid contingents of retail shareholder and outspoken, charismatic CEOs. And both have crucial business issues that hinge on federal government policies, whether it’s in the form of the federal EV tax credits that incentivize sales of electric offerings like Teslas or the fact that Palantir’s single largest customer is the US government. (Oh and there’s also Musk’s other venture, SpaceX, which is a major government contractor.)

Oddly enough, these two companies also happen to be the top two stocks in the S&P 500 (closely followed by Taser maker Axon) since President Trump won the election in November, suggesting that at least some investors are betting on benefits for Tesla and Palantir under the new administration that traditional business metrics don’t quite capture.

Ain’t the free market grand.

More Markets

See all Markets
markets

Gene-editing stocks rally on Bloomberg report that FDA plans to fast-track approval process

Shares of biotechs working with gene-editing treatments rose after the industry’s top regulator told Bloomberg News that the Food and Drug Administration plans to publish a paper in early November outlining the agency’s new, faster approach to approving those treatments.

markets

Getty Images shares moon on licensing deal with Perplexity

Getty Images soared Friday after announcing a multiyear licensing deal with AI search company Perplexity AI. Reuters reports:

Under the agreement, Perplexity will integrate Getty’s API technology into its AI platform workflows, enabling users to access premium visuals while improving image attribution. The collaboration is part of a wider trend of digital platforms signing licensing deals with AI content providers to expand content access while respecting intellectual property rights and generating revenue.

Getty was up as much as 85% in the premarket trading session, but those gains are quickly dropping as holders rush to dump the stock, which has been a truly disastrous long-term trade.

In fact, Getty has had a pretty bizarre ride since it returned to the public markets on July 25, 2022, as part of a SPAC deal — in a previous life it had been publicly traded before being taken private in 2008. Within days of its return, Getty became a minor meme stock, spiking more than 250% before crashing a couple months later.

Since then, the stock’s trajectory has been abysmal. Prior to the announcement of the Perplexity AI deal on Friday, it was down 80% from its trading debut. No wonder people are trying to get out fast.

At last glance, those 85% gains in the premarket have been swamped by sellers, shrinking today’s gain for Getty down to 17%.

markets

AbbVie earnings beat estimates but sag on decline in oncology and aesthetics biz

AbbVie slipped after it reported earnings results that beat Wall Street estimates, but also showed a slowdown in its oncology and aesthetics business.

The company reported adjusted quarterly earnings per share of $1.86, compared to the $1.77 analysts polled by FactSet were expecting, and raised its full-year profit guidance. It also reported revenue at $15.7 billion, higher than the $15.5 billion the Street was penciling in.

But the pharmaceutical giant’s oncology and aesthetics business (sales of Botox and Juvederm) slowed down and missed the Street’s estimates. The latter is sometimes seen as a pulse for consumer sentiment.

Latest Stories

Sherwood Media, LLC produces fresh and unique perspectives on topical financial news and is a fully owned subsidiary of Robinhood Markets, Inc., and any views expressed here do not necessarily reflect the views of any other Robinhood affiliate, including Robinhood Markets, Inc., Robinhood Financial LLC, Robinhood Securities, LLC, Robinhood Crypto, LLC, or Robinhood Money, LLC.